麻豆精选

PhD in Health Sciences, University of Warwick, 2024

MSc in Health Economics and Health Policy, University 麻豆精选, 2008

BSc in Economics and Management, University of the West Indies, Cave Hill Campus, 2006

Peter is an Assistant Professor in Health Economics and Decision Modelling. He joined the Birmingham Centre for Evidence and Implementation Science (BECIS) in January 2025 having previously worked at the University if Warwick for 13 years and the University of Exeter. Peter works with a multidisciplinary team that prepares technology appraisal reviews commissioned by the National Institute for Health and Care Excellence. He was awarded a PhD in from the University of Warwick in 2024, which focussed on the cost-effectiveness of different tests used to identify latent tuberculosis infection in people living with HIV. Prior to joining Warwick Evidence, Peter worked as a Research Fellow in Health Economics at The University of Exeter where he provided health economic support to researchers/clinicians interested in submitting grant applications to various funding bodies to undertake research. 

Peter’s interests include systematically reviewing economic evidence, conducting model-based economic evaluations and economic evaluations alongside clinical trials. His research so far has primarily focused on using economic models to assess the cost-effectiveness of different tests/strategies to screen and treatment for various diseases/conditions including tuberculosis infection in high-risk people, obstructive sleep apnoea, congenital heart defects in newborns, and treatment of people living with multiple sclerosis. Methodologically, he is interested in survival analysis in health technology assessment, and evidence synthesis of test accuracy data and their use in model-based economic analyses.

Peter is interested in supervising students in the following areas:

• Decision analytical modelling in economic evaluation
• Health technology assessment

Peter leads multidisciplinary technology appraisal review (TAR) project teams. Since 2013, Peter has provided critique to over 25 appraisals/assessments with a focus on the health economic evidence comparing different health technologies spanning many diseases/conditions, but mainly cancers and multiple sclerosis. These appraisals aid in the decision-making process on the reimbursement of technologies, efficient use of scarce healthcare resources, access to innovative treatments that leads to improved health outcomes. 

Alongside the TAR-related work, Peter has undertaken systematic reviews and meta-analysis of clinical effectiveness evidence, systematic reviews of cost-effectiveness evidence, and model-based economic analyses, using de novo models. His research spans undertaking economic evaluation of tests to screen for cancer (e.g., recurrent breast cancer and recurrent cervical cancer), latent tuberculosis infection, tyrosinaemia type I, Chron’s disease and congenital heart defects in children. 

Additionally, Peter is a co-applicant on three NIHR Invention for Innovation (i4i) research projects involving digital health technologies and projects based on real-world settings where he provides support on the design of the economic analysis of these innovative technologies. He anticipates that output from this research will lead to change to clinical guidelines to improve patient outcomes, to publications in peer-reviewed journals and to dissemination at relevant conferences. 

Methodologically, Peter is interested in evidence synthesis of test accuracy data, especially in tests used to diagnose tuberculosis infection in high-risk populations. His PhD compiled a body of research that assessed the value of using tuberculin skin test and interferon-gamma release assays as prognostic tests in screening for tuberculosis infection in people living with human immunodeficiency virus. This research portfolio gained interest in the research community leading to collaboration with researchers at the University of Monash, Malaysia, with interests in TB prevention and treatment in a hard-to-reach community. Additionally, there was an interest to learn about experiences in undertaking HTA in the UK setting. 

Peter’s interests are not limited those previously mentioned and would be keen to explore other research areas. For example, the use of health economic evaluation in implementation science.

Association member

• Member of the UK Health Economics Study Group (HESG)
• Member of the International Health Economics Association (iHEA)
• The Professional Society for Health Economics and Outcomes Research (ISPOR)